Generalized Epilepsy
11
0
0
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
18.2%
2 terminated out of 11 trials
77.8%
-8.7% vs benchmark
27%
3 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
Assessment of Multifocal Continuous Theta Burst Transcranial Magnetic Stimulation (cTBS) Effects in Generalized Epilepsy Patients.
Long-term Cardiac Monitoring in Epilepsy
Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy
Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy
Transcranial Direct Current Stimulation (tDCS) in Children and Adolescents With Epilepsy and Depression
Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
Metabolic Abnormalities in Children With Epilepsy